|
Alpha-1-antitrypsin deficiency |
An hereditary disorder of the blood protein Alpha-1
characterised by a reduction of serum levels of Alpha-1, emphysema, and
occasionally liver disease |
|
Anticholinergic |
An agent that blocks the parasympathetic nerves - those
involved in slowing the heart rate, increasing intestinal and gland activity
and relaxing sphincter muscles |
|
Bronchodilator |
A medication given to dilate the airways to allow the
unrestricted passage of air |
|
COPD |
Chronic Obstructive Pulmonary Disease is a slowly
progressive airway disease that causes significant deterioration of lung
function and consequently, disability and death. COPD includes chronic
bronchitis and emphysema |
|
CORD |
Chronic Obstructice Respiratory Disease, Another name for
COPD |
|
Dyspnoea |
Shortness of breath |
|
GOLD |
Global Initiative For Chronic Obstructive Lung Disease |
|
Histo-pathological |
Related to the microscopic structure of diseased tissues |
|
Hypoxaemic |
Deficient amount of oxygen delivered to body tissues |
|
M3-receptor |
M3 receptors receive signals from the brain and play a
pivotal role in regulating the smooth muscle contraction of the lung |
|
SPIRIVA® |
Long-acting M3 blocker. It is a bronchodilator drug developed
specifically for COPD by Boehringer Ingelheim, registered trademark of
tiotropium bromide |
|
Sputum |
Matter ejected from the lungs, bronchi and trachea,
through the mouth |
|
tiotropium |
Tiotropium bromide monohydrate is the active ingredient of SPIRIVA® -
a once-daily inhaled COPD treatment that works through prolonged M3-receptor
blockade |
|
WHO |
World Health Organization |